NEW YORK (GenomeWeb News) – Genetic test development firm Interleukin Genetics today announced it raised $12 million in gross proceeds through a private placement with accredited investors.

The Waltham, Mass.-based firm said its sold about 43.7 million shares of its common stock at $0.2745 per share and issued warrants to purchase an aggregate of about 32.8 million shares of common stock at an exercise price of $0.2745 per share to the investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.